- Email: [email protected]
Wet wrap dressings as therapy for atopic dermatitis
s134
Free couuuunication FCS. Au~oiuuuune diseases
Conclusion: Three-week treatment of atopic patients with extensive lesions (up to 59% of BSA) resulted in low SDZ ASM 981 blood concentrations, at which no systemic effect is expected. New data are being collected during long-tern treatment. FC4-5
Wet wrap dressings dermatitis
as therapy
for atopic
A.P. Oranje, A. Wolkerstorfer, T. van Meurs, F.B. de Waard-van der Spek. Dept. Dermato-venereology, University Hospiral, Rolterdam, The Netherlands Fluticasone propionate 0.05% is a corticosteroid with an improved benefit/risk ratio. Therefore it is suitable for the wet wrap technique. Methods and Materials: A protocol of using fluticasone propionate 0.05% cream-emollient 1:l diluted in the ‘wet-wrap’ method was applied. Results: Eighteen children suffering from severe atopic dermatitis (AD) were enrolled. One child dropped out. The severity of AD was measured by evaluating the objective SCORAD, ranging from 32-72. A significant improvement of AD was observed after 2 weeks. Significant suppression of HPA, as measured by serum cortisol levels in all patients, did not occur, except in three patients with a temporarily depression. Most children were treated for more than 3 months with intermittent wet wraps. Conclusion: This therapy with a potent corticosteroid with minor systemic side-effects is an interesting and promising option in children, but also in adults. The concentration of the fluticasone propionate 0.05% cream-emollient 1: I dilution may be lowered with enhanced safety. Specific immunotherapy in the treatment selected patients with atopic dermatitis: Preliminary announcement
of
Wojciech Silny, Magdalena Czarnecka-Operacz, Maurycy Piotrowski, Pawel Silny. Department of Dermatology, Allergic Diseases Diagnostic Center; University School of Medicine, Poz.n&, 49 Przybyszewskiego Srr; Poland The aim of our study was to evaluate the efficacy of specific immunotherapy with Novo-Helisen Depot in a yearly treatment of selected cases of patents with atopic dermatitis (AD). We investigated 34 patients with AD between 5 and 44 years of age. Detail case history, results of skin prick tests and serum levels of antigen specific IgE were considered for the selection of patients and composition of vaccines for their immunotherapy. After one year of treatment significant clinical improvement was observed in 14 patients treated with Novo-Helisen Depot. In 17 cases clinical improvement was moderate and the treatment was ineffective in the cases of 3 patients. No adverse reaction to the treatment were recorded and none of the patients discontinued immunother.
FC4-7
Peroral ketokonazole dermatitis
treatment
of atopic
P. Lintu, 0. Kortekangas-Savolainen, K. Kalimo, J. Savolainen. Departruenls of Dermarology and Clinical Allergology, University of Turku, Turku, Finland Immediate hypersensitivity to yeasts is seen often in atopic dermatitis (AD), especially in AD of the head, neck and shoulder region. A couple of studies have shown that ketokonazole is effective in the treatment of this type of AD. However the association and impact of the saprophytic Povale growth and /?ovale specific IgE on the treatment have not been studied. We performed a DBPC study of peroral ketokonazole treatment in AD. Altogether 70 patients with AD and positive Povale RAST or skin test were randomized to receive ketokonazole or placebo for 30 days. The saprophytic yeast growth, Rovale RAST and the severity of the eczema (SCORAD) were assessed at days 0.30 and 60. Ketokonazole reduced significantly the saprophytic growth and SCORAD score at day 30 and specific RAST at day 60. The effect of ketokonazole on AD severity was most prominent in patients with pre-treatment positive t?ovale skin growth or moderately positive I?ovale RAST (~20 kU/I) and in women. No significant effect was seen in patients with no P.ovale growth or high Povale RAST (>20 kU/I) and in men.
FCS.
Autoimmune diseases Multiple comedos erythematosus
in discoid
lupus
K. Pramatarov, S. Vassileva, S. Marina. Deparrment of Dermatology, Medical University, Sofia, Bulgaria We report five patients (4 females and one male), aged 2043, with multiple comedos in the lesions of discoid lupus erythematosus (DLE). The comedo lesions were localized in the perioral and nasolabial folds, on the chin and in one patient, in the periauricular areas. The diagnosis of DLE was confirmed by the histologic and immunologic examinations. Several mecha-. nisms can be suggested for comedo formation in DLE lesions: comedo lesions are peculiar expression of an exaggerated follicular hyperkeratosis; comedos in DLE appear in individuals with pronounced seborrhoea and they can be result of prolonged sun damage. FC5-2
Lupus erythematosus associated erythema multiforme-like lesions: syndrome
with Rowell’s
G. Roustan, E. Sutiez, C. Barbadillo, C. Salas, J. Mulero, E. Sfinchez Yus’, A. Sim6n. Clfnica Universitaria Puerra de Hierro; ‘Hospital Clinico San carlos, Madrid, Spain We describe a patient diagnosed of lupus erythematosus (LE) who developed an acute generalized eruption characterized by target-like lesions an mucosal erosions. Biopsy specimens showed an interface dermatitis with many necrotic keratinocytes. Laboratory tests disclosed: ANA (+) l/640 gian-
Free couuuunication FCS. Au~oiuuuune diseases
Conclusion: Three-week treatment of atopic patients with extensive lesions (up to 59% of BSA) resulted in low SDZ ASM 981 blood concentrations, at which no systemic effect is expected. New data are being collected during long-tern treatment. FC4-5
Wet wrap dressings dermatitis
as therapy
for atopic
A.P. Oranje, A. Wolkerstorfer, T. van Meurs, F.B. de Waard-van der Spek. Dept. Dermato-venereology, University Hospiral, Rolterdam, The Netherlands Fluticasone propionate 0.05% is a corticosteroid with an improved benefit/risk ratio. Therefore it is suitable for the wet wrap technique. Methods and Materials: A protocol of using fluticasone propionate 0.05% cream-emollient 1:l diluted in the ‘wet-wrap’ method was applied. Results: Eighteen children suffering from severe atopic dermatitis (AD) were enrolled. One child dropped out. The severity of AD was measured by evaluating the objective SCORAD, ranging from 32-72. A significant improvement of AD was observed after 2 weeks. Significant suppression of HPA, as measured by serum cortisol levels in all patients, did not occur, except in three patients with a temporarily depression. Most children were treated for more than 3 months with intermittent wet wraps. Conclusion: This therapy with a potent corticosteroid with minor systemic side-effects is an interesting and promising option in children, but also in adults. The concentration of the fluticasone propionate 0.05% cream-emollient 1: I dilution may be lowered with enhanced safety. Specific immunotherapy in the treatment selected patients with atopic dermatitis: Preliminary announcement
of
Wojciech Silny, Magdalena Czarnecka-Operacz, Maurycy Piotrowski, Pawel Silny. Department of Dermatology, Allergic Diseases Diagnostic Center; University School of Medicine, Poz.n&, 49 Przybyszewskiego Srr; Poland The aim of our study was to evaluate the efficacy of specific immunotherapy with Novo-Helisen Depot in a yearly treatment of selected cases of patents with atopic dermatitis (AD). We investigated 34 patients with AD between 5 and 44 years of age. Detail case history, results of skin prick tests and serum levels of antigen specific IgE were considered for the selection of patients and composition of vaccines for their immunotherapy. After one year of treatment significant clinical improvement was observed in 14 patients treated with Novo-Helisen Depot. In 17 cases clinical improvement was moderate and the treatment was ineffective in the cases of 3 patients. No adverse reaction to the treatment were recorded and none of the patients discontinued immunother.
FC4-7
Peroral ketokonazole dermatitis
treatment
of atopic
P. Lintu, 0. Kortekangas-Savolainen, K. Kalimo, J. Savolainen. Departruenls of Dermarology and Clinical Allergology, University of Turku, Turku, Finland Immediate hypersensitivity to yeasts is seen often in atopic dermatitis (AD), especially in AD of the head, neck and shoulder region. A couple of studies have shown that ketokonazole is effective in the treatment of this type of AD. However the association and impact of the saprophytic Povale growth and /?ovale specific IgE on the treatment have not been studied. We performed a DBPC study of peroral ketokonazole treatment in AD. Altogether 70 patients with AD and positive Povale RAST or skin test were randomized to receive ketokonazole or placebo for 30 days. The saprophytic yeast growth, Rovale RAST and the severity of the eczema (SCORAD) were assessed at days 0.30 and 60. Ketokonazole reduced significantly the saprophytic growth and SCORAD score at day 30 and specific RAST at day 60. The effect of ketokonazole on AD severity was most prominent in patients with pre-treatment positive t?ovale skin growth or moderately positive I?ovale RAST (~20 kU/I) and in women. No significant effect was seen in patients with no P.ovale growth or high Povale RAST (>20 kU/I) and in men.
FCS.
Autoimmune diseases Multiple comedos erythematosus
in discoid
lupus
K. Pramatarov, S. Vassileva, S. Marina. Deparrment of Dermatology, Medical University, Sofia, Bulgaria We report five patients (4 females and one male), aged 2043, with multiple comedos in the lesions of discoid lupus erythematosus (DLE). The comedo lesions were localized in the perioral and nasolabial folds, on the chin and in one patient, in the periauricular areas. The diagnosis of DLE was confirmed by the histologic and immunologic examinations. Several mecha-. nisms can be suggested for comedo formation in DLE lesions: comedo lesions are peculiar expression of an exaggerated follicular hyperkeratosis; comedos in DLE appear in individuals with pronounced seborrhoea and they can be result of prolonged sun damage. FC5-2
Lupus erythematosus associated erythema multiforme-like lesions: syndrome
with Rowell’s
G. Roustan, E. Sutiez, C. Barbadillo, C. Salas, J. Mulero, E. Sfinchez Yus’, A. Sim6n. Clfnica Universitaria Puerra de Hierro; ‘Hospital Clinico San carlos, Madrid, Spain We describe a patient diagnosed of lupus erythematosus (LE) who developed an acute generalized eruption characterized by target-like lesions an mucosal erosions. Biopsy specimens showed an interface dermatitis with many necrotic keratinocytes. Laboratory tests disclosed: ANA (+) l/640 gian-